Ontology highlight
ABSTRACT:
SUBMITTER: Baba H
PROVIDER: S-EPMC4741821 | biostudies-other | 2015 Oct
REPOSITORIES: biostudies-other
Baba Hideo H Baba Yoshifumi Y Uemoto Shinji S Yoshida Kazuhiro K Saiura Akio A Watanabe Masayuki M Maehara Yoshihiko Y Oki Eiji E Ikeda Yasuharu Y Matsuda Hiroyuki H Yamamoto Masakazu M Shimada Mitsuo M Taketomi Akinobu A Unno Michiaki M Sugihara Kenichi K Ogata Yutaka Y Eguchi Susumu S Kitano Seigo S Shirouzu Kazuo K Saiki Yasumitsu Y Takamori Hiroshi H Mori Masaki M Hirata Toshihiko T Wakabayashi Go G Kokudo Norihiro N
Oncotarget 20151001 32
Our previous study showed that administering oxaliplatin as first-line chemotherapy increased ERCC1 and DPD levels in liver colorectal cancers (CRCs) metastases. Second, whether the anti-VEGF monoclonal antibody bevacizumab alters tumoral VEGFA levels is unknown. We conducted this multicenter observational study to validate our previous findings on ERCC1 and DPD, and clarify the response of VEGFA expression to bavacizumab administration. 346 CRC patients with liver metastases were enrolled at 22 ...[more]